Summary Of Loading Off Bottom - As At Close December

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
155
Summary Of Loading Off Bottom - As At Close December 24.

Bought at .4000:

Aug 29: 400

Bought at .3500:

Aug 29: 100

Bought at .3000 / .3200 / .3275

Aug 28: 42,000
Oct 24: 2,599
Oct 26: 7,635
Oct 29: 4,915
Oct 30: 900

Total: 58,049

Bought at .2500 / .2553 / .2600 / .2779 / .2788 / .2800 / .2843 / .2887 / .2888 / .2998 / .2999

Sep 24: 45,374
Sep 15: 124
Oct 2: 990
Oct 18: 26,616
Oct 19: 25,000
Oct 22: 11,500
Oct 23: 10,000
Oct 24: 10,000
Jan 2: 1,000

Total: 130,604

Bought at .2045 / .2100 / .2194 / .2300 / .2325 / .2350 / .2400 / .2469:

Aug 29: 200
Sep 24: 5,194
Sep 27: 2,425
Oct 1: 10,000
Oct 12: 155
Oct 22: 520
Oct 26: 8
Oct 30: 30
Nov 5: 1
Nov 8: 3,469
Nov 9: 800
Nov 27: 5,150
Dec 4: 400
Dec 14: 1,490
Dec 18: 3,245
Dec 28: 132
Jan 7: 500
Feb 14: 503
Oct 29: 68

Total: 34,280

Bought at .2000:

Aug 28: 63,000
Sep 21: 6,499
Sep 25: 10
Sep 26: 2,500
Feb 14: 100
Feb 26: 500
Feb 27: 383
Mar 4: 533

Total: 73,025

Bought at .1600 / .1650 / .1670 / .1690 / .1700 / .1800 / .1900 / .1940 / .1995:

Aug 31: 800
Sep 21: 2,683
Oct 2: 200
Oct 8: 10,000
Oct 15: 613
Oct 16: 5,187
Oct 17: 2,500
Nov 8: 9,100
Nov 9: 1,300
Nov 12: 10,130
Nov 13: 10,000
Nov 14: 8,008
Jan 10: 22,000
Mar 21: 100
Mar 22: 100

Total: 80,621

Bought at .1500 / .1501 / .1510 / .1525 /.1530 / .1550:

Aug 31: 1,990
Sep 21: 14,154
Oct 10: 413
Oct 11: 300
Oct 12: 200
Oct 15: 9,387
Nov 16: 1
Nov 19: 66
Nov 27: 150
Dec 31: 764
Jan 7: 11
Jan 8: 3,572
Jan 22: 2
Feb 1: 1,500
Mar 4: 1,180
Mar 6: 150

Total: 33,840

Bought at .1405 / .1425 / .1440 / .1450 / .1475:

Sep 13: 1,541
Sep 14: 580
Sep 18. 20,000
Aug 6: 100
Aug 26: 4,000

Total: 26,221

Bought at .1400:

Aug 31: 6,800
Sep 5: 100
Sep 12: 19,900

Total: 26,800

Bought at .1300 / .1350:

Aug 31: 9,900
May 21: 100
May 22: 100

Total: 10,100

Bought at .1200 / .1250 / .12555 / .1270:

Aug 30: 8,000
Aug 31: 999
Sep 17: 5,100
Sep 18: 6,200
Sep 20: 1,260
Nov 30: 75
Dec 3: 50
Dec 6: 9
Dec 10: 1
Dec 17: 1
Dec 28: 700
Sep 13: 100
Sep 30: 110

Total: 22,605

Bought at .1011 / .1045 / .10505 / .1051 / .1075 / .1100 / .1150

Sep 5: 5,000
Dec 24: 20
Jan 9: 33
Jan 22: 1
Jan 24: 4
Jan 25: 1,001
Jan 26: 7,493
Feb 8: 400
Feb 20: 5
Feb 21: 2
Mar 12: 2
Apr 2: 311
May 7: 480
Sep 5: 9
Oct 10: 3,000
Oct 11: 11,675

Total: 29,436

Bought at .1000:

Aug 28: 245,000
Aug 31: 55,512
Sep 4: 9,905
Sep 12: 5,000
Feb 20: 5
Feb 26: 100
Feb 27: 528
Feb 28: 850
Mar 1: 65
Mar 4: 1
Mar 6: 206
Mar 8: 3,277
Mar 19: 300
Apr 2: 4,397
Apr 3: 167
Apr 4: 1,202
Apr 5: 1,500
Apr 15: 2,923
Apr 22: 1
Apr 23: 201
May 2: 2
May 7: 30
May 10: 1
May 14: 1,363
May 15: 55
May 21:18
May 23: 1,000
Jul 1: 2,000
Sep 4: 15,821 [all bought on ask]
Oct 7: 4,000
Oct 9: 1,000
Oct 10: 7,175
Oct 11: 8,325

Total: 371,930

Bought at .0900:

Sep 12: 995

Bought at .080 / .0850 / .0875:

Sep 10: 3,370
Sep 11: 3,099
Oct 7: 4
Oct 10: 1,500 [bought by invisible bidder at .1000]
Oct 11: 10 [bought by invisible bidder at .1000]

Total: 4,984

Bought at .0701 / .0750 / .0751:

Sep 5: 26
Sep 6: 2,917
Sep 7: 4,926
Sep 10: 6,390
Oct 14: 1,145 [paint down set at .0751 below invisible bid much higher]
Oct 16: 13,599 [paint down set at .0750 below invisible bid much higher]
Oct 21: 25 [paint down set at .0750 below invisible bid much higher]
Oct 24: 100 [paint down set at .0750 below invisible bid much higher]
Oct 25: 1,500 [paint down set at .0750 below invisible bid much higher]
Oct 29: 10 [paint down set at .0750 below invisible bid much higher]
Oct 31: 90 [paint down set at .0745 below invisible bid much higher]
Nov 1: 6,276 [paint down set at .0750 below invisible bid much higher]

Total: 36,604

Bought at .0050 > .0700:

May 28: 4,300 [ignoring 3,800 short / cover mirror trade]
Jun 18: 1,000 [filling hidden bid at .1000 from shorted paint down]
Jul 19: 500 [filling hidden bid from paint down]
Jul 23: 1,000
Jul 24: 7,000
Sep 3: 625 [paint down bought at .0160]
Sep 13: 1,000 [paint down bought at .0160]
Sep 17: 390 [paint down bought mainly at .0120]
Sep 24: 475 [paint down bought at .0150]
Oct 18: 250 [paint down set at .0385 below invisible bid much higher]
Oct 21: 50 [paint down set at .0385 below invisible bid much higher]
Nov 4: 100 [paint down set at .0475 below invisible bid much higher]
Nov 7: 50 [paint down set at .0625 below invisible bid much higher]
Nov 11: 4 [paint down set at .0500 below invisible bid much higher]
Dec 4: 2,857 [paint down set at .0600 below invisible bid much higher]
Dec 5: 7,143 [paint down set at .0300 below invisible bid much higher]
Dec 6: 28 [paint down set at .0300 below invisible bid much higher]
Dec 19: 6 [paint down set at .0200 below invisible bid much higher]
Dec 20: 300 [paint down set at .0300 below invisible bid much higher]
Dec 24: 36 [paint downs set at .0225/.0300 below invisible bid much higher]

Total: 27,114


Notes:
Nobody had .1s (.0001s) previously.
Very few had .2 (.0002s) previously - only 5M from 2018 prior to Aug 28.




American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading